2006
DOI: 10.1007/s10067-006-0375-2
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of refractory temporal arteritis with adalimumab

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
19
0
3

Year Published

2011
2011
2017
2017

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 50 publications
(22 citation statements)
references
References 10 publications
0
19
0
3
Order By: Relevance
“…Classical disease therapy relies on a high dose of GC administration once the clinical finding is suggestive of the disease [25,26]. Relapse is common in 60-70% of patients thus, other therapeutic modalities are required [23,27,28]. A meta-analysis in 2014 [29], included five studies about anti TNF alpha agents in GCA.…”
Section: Giant Cell Arteritismentioning
confidence: 99%
“…Classical disease therapy relies on a high dose of GC administration once the clinical finding is suggestive of the disease [25,26]. Relapse is common in 60-70% of patients thus, other therapeutic modalities are required [23,27,28]. A meta-analysis in 2014 [29], included five studies about anti TNF alpha agents in GCA.…”
Section: Giant Cell Arteritismentioning
confidence: 99%
“…Ингибиторы фактора некроза опухоли аль-фа (ФНО-α) эффективны при большом количестве воспалительных процессов, в том числе при рев-матоидном артрите и анкилозирующем спонди-лите [27]. В настоящее время отсутствуют доказа-тельства того, что применение анти-ФНО-терапии имеет преимущество в лечении ГКА, несмотря на отдельные сообщения об успешном исполь-зовании этой группы лекарственных средств [4].…”
Section: ингибиторы фактора некроза опухоли альфаunclassified
“…TNF has been demonstrated in up to 60% of the cells in all areas of inflamed arteries (297), and inhibition of this cytokine may be an attractive therapeutic option in GCA. Early case reports (298,299,300,301,302,303,304,305) of favorable response to TNF inhibitors indicated that biological therapy could be an alternative to CS or at least be used in patients failing to respond to CS. However, suggestions of efficacy of TNF inhibitors have not withstood further drug trials.…”
Section: Alternative Treatment Strategiesmentioning
confidence: 99%